# Allurion Technologies

Allurion Technologies is an Asset Manager based in Natick, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Natick, United States
- **Region:** North America
- **Address:** Natick, MA, United States
- **Founded:** 2009
- **Assets under management:** Undisclosed
- **Website:** allurion.com

## Regulatory record

- **Reports private funds:** No

## About

Allurion Technologies was co-founded by Shantanu Gaur, a physician, and Samuel Levy, an engineer, in 2009. The company developed the Elipse Balloon, the only swallowable, fluid-filled gastric balloon for weight loss that is expelled naturally without endoscopy. Wealth origin is not publicly disclosed for the founders or the firm's principals. Allurion's strategy centers on product sales of its Elipse device, supplemented by a subscription-based digital coaching app that provides behavioral and nutritional support. Revenue is reported quarterly in SEC filings. The company went public via a SPAC merger with Compute Health Acquisition Corp. in August 2022, raising approximately $46.7M in gross proceeds. As of 2024, Allurion reported cumulative placements in over 100,000 patients across more than 40 countries. The company maintains its headquarters in Natick, Massachusetts, with a research facility in the region. In 2023, Allurion launched a direct-to-consumer program in the United States via its website. A structural differentiator is Allurion's combination of a medical device with a digital health platform, creating a vertically integrated weight-loss solution that bypasses traditional clinic-based models. This model reduces procedural costs and expands access to patients who lack insurance coverage for conventional bariatric procedures.

## Sectors

- MedTech
- Digital Health
- Healthcare Services

## People

- Shantanu Gaur — CEO and Co-Founder
- Samuel Levy — Co-Founder

## Questions

### Who runs investment decisions at Allurion Technologies?

Allurion is a publicly traded medical device company, not a family office. Investment decisions are made by the board of directors and executive team, led by CEO Shantanu Gaur. No family office arm or affiliated investment entity is publicly known.

### How does Allurion generate revenue?

Allurion generates revenue primarily through sales of its Elipse gastric balloon system to clinics and hospitals, along with a subscription-based digital weight-loss coaching app called the Allurion Program. Revenue is recognized upon device delivery and app subscriptions, per the firm's SEC filings.

### What investment stages does Allurion target?

Allurion does not make investments; it is a commercial-stage company that develops and markets medical devices. It has raised venture and public capital for its operations.

### Which sectors does Allurion explicitly avoid?

Allurion focuses exclusively on MedTech and digital health for weight management. It has no publicly stated avoidance of any sector outside its core business.

### How is Allurion related to Compute Health Acquisition Corp?

Allurion merged with Compute Health Acquisition Corp., a special purpose acquisition company (SPAC), in August 2022. The deal provided Allurion with public listing and capital. Compute Health was sponsored by existing Allurion investors.

## Related profiles

- [Mynd.ai, Inc.](https://altss.com/profile/myndai-inc)
- [Armlogi Holding Corp.](https://altss.com/profile/armlogi-holding-corp)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/allurion-technologies-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology